TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Birthweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Objective Response Rates (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Blood Flow Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical laboratory evaluations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma & CSF glycine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence of nephropathies induced by the injection of iodinate contrast medium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Insulin resistance (HOMA index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Triglycerides, HDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: decrease body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Composite Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Yale Global Tic Severity Scale (YGTSS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurological specific cause of death
Endpoint domain: Mortality/survival
Primary endpoint: Change in GRASSP strength subscore
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ossification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants that achieve tolerance to milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-month relapse-free survival
Endpoint domain: Mortality/survival
Primary endpoint: PTSD Symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: allosensitization after complete islet graft loss
Endpoint domain: Adverse events/effects
Primary endpoint: Cerebral consequences of dopaminergic dysregulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants Who Used Dual Contraception or Safer Conception Method
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Outcome inferencing in the probe test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease-free intervals (DFIs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kidney Function Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Overall Favorable Response to Therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: One or More Drug-Related Adverse Experiences
Endpoint domain: Adverse events/effects
Primary endpoint: CYP2D6 Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Self-Injurious Thoughts and Behaviors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Umbilical cord tissue staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Umbilical blood measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ganglion cell-inner plexiform layer (GCIPL) thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in retinal nerve fiber layer (RNFL) thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in central subfield thickness (CST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in knowledge regarding reporting suspected child abuse
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Microbiological Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Side effects from laser treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Neuropathic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Both a Clinical and a Bacteriological Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Richmond Agitation-Sedation Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Richmond Agitation-Sedation Scale Score at 8 Hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clopidogrel active metabolite pharmacokinetic parameters (Cmax and AUC0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of incidents of Treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of incidents of adverse events of special interest (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of incidents of serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: End of Treatment Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Anti-Mullerian Hormone (AMH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: All-cause hospital mortality by day 90
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Who Had Hypotensive Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Perceived Stress Levels
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mood Changes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall survival (30-day mortality)
Endpoint domain: Mortality/survival
Primary endpoint: 30 Day Composite Safety Endpoint
Endpoint domain: Adverse events/effects
Primary endpoint: 30 Day Treatment Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Who Demonstrate Complete or Partial Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Who Demonstrate Early Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma metabolite biomarkers for neuronal repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: structural changes following ischemic strokes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: percent of subjects remitting from their index affective episode
Endpoint domain: Mortality/survival
Primary endpoint: incidence of relapse during continuation treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Change in WSRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or absence of cast sores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Size of cast sores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Grade of cast sores using Wagner's Classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Evidence of white matter hyperintensities or subclinical ischaemic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall analgesic in 24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of cesarean section niche
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Best response (Complete Response or Partial Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carotid Artery Stiffness (Beta-stiffness Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Carotid Artery Stiffness (Pulse Wave Velocity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of Carotid Artery Plaque Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Motor Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Motor Evoked Potentials (MEPs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PSA Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in sexual activity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Visual acuity test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eye movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Field of vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular Pressure Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of surgical wound infection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Mean Average Pain Intensity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3 or Higher Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Grade 3 or Higher Adverse Events Related to Study Drugs
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline of mechanical measurement for stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of severity for stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of Muscle tone measurement for stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of Muscle strength measurement for stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients prognosis
Endpoint domain: Mortality/survival
Primary endpoint: Body Surface Area (BSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PET SUV (Standardized Uptake Value)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to Antidepressant Medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidents of participants that drop-out of treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Incidents of participants that refuse treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment and Acceptability Adherence Scale (TAAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: area of foveal avascular zone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of generating activated marrow infiltrating lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence rate of serious infections
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of malignancies
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of autoimmune disorders
Endpoint domain: Adverse events/effects
Primary endpoint: Neurosensory alteration - sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent Change in Biomarker (GLI2 Protein) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: child's pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shoulder pain degrees
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low Back Pain Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft versus host disease (GVHD)-free relapse-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Propionibacterium colonization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Best Corrected Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: St George's Respiratory Questionnaire (SGRQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of patients at risk who received flu vaccine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pharmacokinetic data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy and manageable toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Social Withdrawal subscale score
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Mortality and disability evaluation
Endpoint domain: Mortality/survival
Primary endpoint: Presence of complications at delivery or after C-section
Endpoint domain: Adverse events/effects
Primary endpoint: Symptom control of heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: First attempt success rate of tracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: rate of dislocation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of hospitalized cancer patients with average severe pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom Checklist-20 Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of drug-related Grade ≥3 Adverse Events (AEs) or dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Hematologic response based on normalization of conversion of any baseline cytopenia or anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Doubling of PSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Allergan Hand Volume Deficit Scale (AHVDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: effective response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure of medical treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Change of Median Individual Allergen Tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Acute Neurological Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CPR knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: overall survival at 2-year interval
Endpoint domain: Mortality/survival
Primary endpoint: disease-free survival at 2-year interval
Endpoint domain: Mortality/survival
Primary endpoint: distant metastasis-free survival at 2-year interval
Endpoint domain: Mortality/survival
Primary endpoint: Metabolic syndrome risk ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vd/F
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Gross Motor Function Measure - 88
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients receiving TT and IO therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients switching from TT 1L therapy to IO 2L therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients switching from IO 1L therapy to TT 2L therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: clinically relevant laryngeal and bronchial morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Liver-related clinical outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Risk of Cancer with Specific Mutations
Endpoint domain: Mortality/survival
Primary endpoint: Unhealthy drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol related problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Overall Rheumatoid Arthritis Disease Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CtDNA level measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Real-world overall survival (rwOS)
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Presenting Reflux Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With Esophageal Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With Gastroesophageal Reflux Disease (GERD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Central and peripheral hemodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of HIV patients with protective YF NT ≥ 1:10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Home blood pressure measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HDL function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fecal flora cultures (Count of colonies/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum immunoglobulins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lymphocyte Subpopulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibiotic Prescription
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of patients with viral reactivation of Epstein-Barr Virus
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with viral reactivation of Human Herpes Virus 6
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with viral reactivation of Human Herpes Virus 7
Endpoint domain: Adverse events/effects
Primary endpoint: technical success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: access success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to 12 hours (AUC [0-12])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Total Sedentary Time Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in airway inflammatory biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical or laboratory toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Surgical complication
Endpoint domain: Adverse events/effects
Primary endpoint: Change in menopausal symptom score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Epithelial ovarian cancer
Endpoint domain: Mortality/survival
Primary endpoint: Aesthetic Improvement of Midface
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Forced Vital Capacity (FVC) at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline Forced Expiratory volume in 1 second (FEV1) at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline Peripheral Muscle strength at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline Balance at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline distance covered in Six-Minute Walk Test at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FLT-uptake in colorectal liver metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: histologically determined proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of Exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Drug Concentration (Cmax) of Denosumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Drug Concentration-time Curve From Time 0 to 18 Weeks Post-dose (AUC0-18 Weeks) of Denosumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with clinically significant changes in vital signs (blood pressure, pulse rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient cough symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Therapy duration
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Progression-free Survival Rate at 6 Weeks
Endpoint domain: Mortality/survival
Primary endpoint: Progression-free Survival Rate at 12 Weeks
Endpoint domain: Mortality/survival
Primary endpoint: Progression-free Survival Rate at 18 Weeks
Endpoint domain: Mortality/survival
Primary endpoint: Clinically elevated levels of PTSD
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Verbal communication
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning